IPO - Aptose Biosciences Inc.

Form Type: S-1

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525026207

Filing Summary: This registration statement on Form S-1 relates to the resale of 12,030,218 common shares of Aptose Biosciences Inc. by Keystone Capital Partners, LLC, under a Common Share Purchase Agreement dated February 7, 2025. The prospectus outlines the company's focus on developing precision medicines for oncology, specifically for hematology, with its lead product Tuspetinib, aimed at treating acute myeloid leukemia (AML). The company is conducting a Phase 1/2 clinical trial of Tuspetinib combined with venetoclax and a hypomethylating agent. Although no proceeds from the sales of shares will be received directly by Aptose, it may raise funds through sales of shares to the Selling Shareholder as per the agreement. The document contains forward-looking statements regarding the company's future performance and the risks involved with its clinical trials and drug development, emphasizing the necessity for substantial funding and the inherent uncertainties within biopharmaceutical development.

Document Link: View Document